Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Betaxolol twice daily (dose NR) (n=182)
B. Placebo (n=168)

Sample Characteristics

1. N
A. Betaxolol twice daily (dose NR) (n=182)
B. Placebo (n=168)
Total
2. Baseline population
A. Betaxolol twice daily (dose NR) (n=182)
B. Placebo (n=168)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderMean IOP decrease
  • All Participants
  • end of study
CategoricalVision disorderProgression to glaucomatous visual field loss, 60 months
  • All Participants
  • 60 months

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (Mean IOP decrease)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Betaxolol twice daily (dose NR) (n=182) B. Placebo (n=168)
vs.
end of study
Mean IOP decrease
p value
Within Arm ComparisonsNet Comparisons
A. Betaxolol twice daily (dose NR) (n=182) B. Placebo (n=168)
vs.

Vision disorder (Progression to glaucomatous visual field loss, 60 months)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Betaxolol twice daily (dose NR) (n=182) B. Placebo (n=168)
60 months
Mean IOP decrease
Odds Ratio (OR)
Total (N analyzed)
95% CI low (OR)
Events
95% CI high (OR)
Percentage
p value
Within Arm ComparisonsNet Comparisons
A. Betaxolol twice daily (dose NR) (n=182) B. Placebo (n=168)